↓ Skip to main content

Dove Medical Press

Article Metrics

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date

Overview of attention for article published in Drug Design, Development and Therapy, January 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (69th percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter
6 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
50 Mendeley
Title
Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
Published in
Drug Design, Development and Therapy, January 2017
DOI 10.2147/dddt.s104233
Pubmed ID
Authors

Chiara Crotti, Maria Gabriella Raimondo, Andrea Becciolini, Martina Biggioggero, Ennio Giulio Favalli

Abstract

The introduction of biological therapies into clinical practice has dramatically modified the natural history of chronic inflammatory diseases, such as rheumatoid arthritis (RA). RA is a systemic autoimmune disease that causes articular damage and has a great negative impact on patients' quality of life. Despite the wide spectrum of available biological treatments, ~30% of RA patients are still unresponsive, resulting in high disability and increased morbidity and mortality. In the last few decades, the scientific knowledge on RA pathogenesis vastly improved, leading to the identification of new proinflammatory molecules as potential therapeutic targets. Several in vitro and in vivo studies showed that granulocyte-macrophage colony-stimulating factor (GM-CSF), known to be a hematopoietic factor, is also one of the proinflammatory cytokines involved in macrophage activation, crucial for the pathogenic network of RA. Mavrilimumab, a human monoclonal antibody targeting the subunit α of GM-CSF receptor, was recently developed as a competitive antagonist of GM-CSF pathway and successfully adopted in human trials for mild to moderate RA. Mavrilimumab phase I and phase II studies reported an overall good efficacy and safety profile of the drug, and these encouraging results promoted the initiation of worldwide phase III studies. In particular, 158-week results of phase II trials did not show long-term lung toxicity, addressing the major concern about this target of pulmonary alveolar proteinosis development. However, further clinical studies conducted in larger RA populations are needed to confirm these promising results. This review summarizes the biological role of GM-CSF in RA and the preclinical and clinical data on mavrilimumab and other monoclonal antibodies targeted on this pathway as an alternative therapeutic option in RA patients who are unresponsive to conventional biological drugs.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 50 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 13 26%
Student > Ph. D. Student 6 12%
Other 5 10%
Student > Master 4 8%
Professor 3 6%
Other 7 14%
Unknown 12 24%
Readers by discipline Count As %
Medicine and Dentistry 10 20%
Biochemistry, Genetics and Molecular Biology 8 16%
Pharmacology, Toxicology and Pharmaceutical Science 5 10%
Nursing and Health Professions 4 8%
Immunology and Microbiology 3 6%
Other 7 14%
Unknown 13 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 June 2020.
All research outputs
#4,342,381
of 15,799,327 outputs
Outputs from Drug Design, Development and Therapy
#236
of 1,598 outputs
Outputs of similar age
#108,295
of 358,328 outputs
Outputs of similar age from Drug Design, Development and Therapy
#9
of 42 outputs
Altmetric has tracked 15,799,327 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 1,598 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 358,328 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.